drugset / Trial / NCT04866381
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.
Timeline
- Start
- 2021-04
- Primary completion
- 2023-04
- Completion
- 2023-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Dalpiciclib | Small molecule | — | — |
| Subject | Famitinib | Small molecule | — | — |